UAB Cancer Prevention and Control Training Program (T32)
UAB Cancer Prevention and Control Training Program (T32)
批准号:
10427303
负责人:
Ritu Aneja
金额:
$44.4万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-07-13 至 2024-06-30
中文摘要
1988年,亚拉巴马大学伯明翰分校(UAB)癌症预防和控制培训计划
(CPCTP)是根据R25机制建立的,已培训了154名博士前和博士后研究员,
过去的28年。CPCTP位于南部腹地,一个以贫困和健康差距为标志的地区,
为寻求研究职业的不同和弱势背景的学生提供了一个重要的桥梁
癌症预防和控制。目前,55%的CPCTP学员是服务不足的少数民族,65%是
女性与国家癌症研究所的使命一致,致力于国家的行为,生物医学和临床研究
(PAR-16-152),我们寻求将CPCTP过渡到T32机制,以便我们
我可以继续培养一批训练有素的科学家,他们已经做出了重大的职业承诺,
癌症预防和控制研究(1-2年3名博士前和3名博士后研究员,4名博士前和4名博士后研究员)
3-5年的博士研究员,每次任命的计划期限为3年)。超过90%的毕业生
从我们目前的周期积极从事研究事业显示成功。我们提出的T32增加了
CPCTP的许多新组件,同时保留了那些对我们成功至关重要的组件,例如,我们
团队科学的多学科方法和强大的团队导师从32名教师谁是成员的
UAB癌症控制和人口科学及癌症化学预防计划
癌症中心(CCC)-全国首批7个NCI指定的CCC之一。我们的努力得到了坚实的支持,
UABCCC的财政承诺和我们提出的目标是:1)招募,教育,培训和评估
来自不同学科的博士前和博士后研究员,在癌症方面进行跨学科研究
(2)招募一批多样化的合格受训人员,包括少数民族成员;
组,(即,非洲裔美国人、拉丁美洲人/西班牙裔和其他弱势群体),并利用UAB的
在癌症预防框架内促进健康差距研究的网络和资源
3)提供专业的核心教学和量身定制的研究课程和丰富的学习机会
在癌症预防和控制中(例如,研讨会、赠款准备/模拟审查)、补充(不
重复)其他UAB培训计划; 4)促进癌症独立研究事业的发展
预防和控制,由在受资助的项目中建立了跟踪记录的高级教师进行指导。
研究; 5)通过额外的课程,额外的学位(即,MSPH),
并获得独立的研究奖学金或职业奖(例如,F31/32、K99、DP 5); 6)教育我们的
在负责任的研究行为和专业发展领域的学员,将提高
他们未来在大学、私立机构或联邦政府内的研究事业中取得的成功;
7)强调跨学科研究训练(团队科学),使受训者获得at
至少两个研究领域,并提高他们未来与其他领域的专业人士合作的能力。
英文摘要
In 1988, the University of Alabama at Birmingham (UAB) Cancer Prevention and Control Training Program
(CPCTP) was established under an R25 mechanism and has trained 154 pre- and post-doctoral fellows over
the past 28 years. Located in the Deep South, an area marked by poverty and health disparities, the CPCTP
provides a critical bridge for students from diverse and disadvantaged backgrounds who seek research careers
in cancer prevention and control. Currently, 55% of CPCTP trainees are underserved minorities, and 65% are
female. Consonant with NCI's mission to address the nation's behavioral, biomedical, and clinical research
needs for a diverse workforce (PAR-16-152), we seek to transition our CPCTP to a T32 mechanism, so that we
can continue to prepare a diverse pool of highly-trained scientists who have made a major career commitment
to cancer prevention and control research (3 pre- & 3 post-doctoral fellows in years 1-2, and 4- pre & 4- post
doctoral fellows in years 3-5, with a planned duration of 3-years for each appointment). Over 90% of graduates
from our current cycle are actively engaged in research careers showing success. Our proposed T32 adds
many novel components to the CPCTP, while retaining those that have been key to our success, e.g., our
team science multidisciplinary approach and strong team mentorship from 32 faculty who are members of the
Cancer Control and Population Sciences and Cancer Chemoprevention Programs of the UAB Comprehensive
Cancer Center (CCC) - one of the nation's first 7 NCI-designated CCCs. Our efforts are supported by a solid
financial commitment by the UABCCC and our proposed aims are to: 1) recruit, educate, train and evaluate
pre- and postdoctoral fellows from diverse academic disciplines to conduct interdisciplinary research in cancer
prevention and control; 2) recruit a diverse cadre of well-qualified trainees who include members of minority
groups, (i.e., African-Americans, Latinos/ Hispanics, and other disadvantaged groups), and capitalize on UAB's
networks and resources to promote research in health disparities within the framework of cancer prevention
and control; 3)provide a specialized core didactic and tailored research curricula and rich learning opportunities
in cancer prevention and control (e.g., seminars, grant preparation/mock reviews), that complement (not
duplicate) other UAB training programs; 4) foster the development of independent research careers in cancer
prevention and control through mentoring by senior faculty who have established track records in funded
research; 5) further the development of all trainees via additional coursework, additional degrees (i.e., MSPH),
and obtaining independent research fellowships or career awards (e.g., F31/32, K99, DP5); 6) educate our
trainees in the Responsible Conduct of Research and in areas of professional development that will enhance
their future successes in research careers at universities, private institutions, or within the federal government;
and 7) emphasize interdisciplinary research training (team science) to enable trainees to gain competence in at
least two research areas and enhance their future ability to collaborate with professionals in other areas.
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1002/cam4.6710
发表时间:
2023-12
期刊:
Cancer medicine
影响因子:
4
作者:
[]
通讯作者:
Health behaviors and well-being among those "living" with metastatic cancer in Alabama.
阿拉巴马州转移性癌症“生活者”的健康行为和幸福感。
DOI:
10.1007/s00520-021-06583-1
发表时间:
2022
期刊:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
影响因子:
--
作者:
[Bail,JenniferR, Bail,SumanthV, Cagle,Jessica, Tiesi,Koriann, Caffey,Jayla, Bakitas,Marie, Demark-Wahnefried,Wendy]
通讯作者:
Demark-Wahnefried,Wendy
DOI:
10.1111/jth.15284
发表时间:
2021-05
期刊:
Journal of thrombosis and haemostasis : JTH
影响因子:
--
作者:
[Avila L, Cullinan N, White M, Gaballah M, Cahill AM, Warad D, Rodriguez V, Tarango C, Hoppmann A, Nelson S, Kuhn T, Biss T, Weiss A, Temple M, Amaral JG, Amiri N, Xavier AC, Renzi S, Brandão LR]
通讯作者:
Brandão LR
Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance.
克服同源重组水平和PARP抑制剂耐药性的策略。
DOI:
10.1158/1535-7163.mct-20-0992
发表时间:
2021-09
期刊:
Molecular cancer therapeutics
影响因子:
5.7
作者:
[]
通讯作者:
DOI:
10.1002/cam4.4095
发表时间:
2021-08
期刊:
Cancer medicine
影响因子:
4
作者:
[Behring M, Ye Y, Elkholy A, Bajpai P, Agarwal S, Kim HG, Ojesina AI, Wiener HW, Manne U, Shrestha S, Vazquez AI]
通讯作者:
Vazquez AI
共 11 条
MARC Supplement at Georgia State University: Workforce Diversity Through Enhanced Mentoring
-
批准号:10394018
-
项目类别:
-
资助金额:$6.67万
-
财政年份:2019
-
负责人:Ritu Aneja
-
依托单位:
HSET as a racial disparity biomarker for TNBC patients
-
批准号:9898334
-
项目类别:
-
资助金额:$76.35万
-
财政年份:2019
-
负责人:Ritu Aneja
-
依托单位:
MARC at Georgia State University: Workforce Diversity through Honors Undergraduates
-
批准号:10166878
-
项目类别:
-
资助金额:$35.06万
-
财政年份:2019
-
负责人:Ritu Aneja
-
依托单位:
HSET as a racial disparity biomarker for TNBC patients
-
批准号:10632100
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Ritu Aneja
-
依托单位:
HSET as a racial disparity biomarker for TNBC patients
-
批准号:10619237
-
项目类别:
-
资助金额:$55.13万
-
财政年份:2019
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr
-
批准号:8968791
-
项目类别:
-
资助金额:$4.77万
-
财政年份:2015
-
负责人:Ritu Aneja
-
依托单位:
A novel racial disparity marker for risk prediction in triple negative breast cancer patients
-
批准号:8997736
-
项目类别:
-
资助金额:$20.75万
-
财政年份:2015
-
负责人:Ritu Aneja
-
依托单位:
Enhancing prognostic power of tumor grade by revisiting Ki67-mitosis relationship
-
批准号:8895609
-
项目类别:
-
资助金额:$7.4万
-
财政年份:2015
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr
-
批准号:9149174
-
项目类别:
-
资助金额:$30.71万
-
财政年份:2014
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr
-
批准号:8930931
-
项目类别:
-
资助金额:$30.71万
-
财政年份:2014
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr
-
批准号:9339617
-
项目类别:
-
资助金额:$30.32万
-
财政年份:2014
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr
-
批准号:8774495
-
项目类别:
-
资助金额:$30.71万
-
财政年份:2014
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy
-
批准号:8518273
-
项目类别:
-
资助金额:$28.18万
-
财政年份:2012
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy
-
批准号:9320098
-
项目类别:
-
资助金额:$4.56万
-
财政年份:2012
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy
-
批准号:9086291
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2012
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy
-
批准号:8676746
-
项目类别:
-
资助金额:$29.08万
-
财政年份:2012
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy
-
批准号:9064260
-
项目类别:
-
资助金额:$4.81万
-
财政年份:2012
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy
-
批准号:8345799
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2012
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy
-
批准号:8839353
-
项目类别:
-
资助金额:$4.67万
-
财政年份:2012
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy
-
批准号:8850404
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2012
-
负责人:Ritu Aneja
-
依托单位:
海外基金